Tuesday, November 24, 2009, 9:18pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares, Sign-in or Register

Endo Pharmaceuticals Holdings Inc. (ENDP)

 At 16:00 EST: 22.62 USD  Down 0.13 (0.57%)  
MORE ON ENDP
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Endo Pharmaceuticals Holdings I (NasdaqNM:ENDP) Delayed quote dataEdit
After Hours: 22.62 0.00 (0.00%) as of 4:59pm EST on 11/24/09
Last Trade: 22.62 USD
Trade Time: 4:00PM EST
Change: Down 0.13 (0.57%)
Prev Close: 22.75
Open: 22.74
Bid: 21.97 x 100
Ask: 23.24 x 100
1y Target Est: 35.00
Day's Range: 22.45 - 22.88
52wk Range: 15.75 - 26.14
Volume: 826,010
Avg Vol (3m): 1,530,590
Market Cap: 2.65B
P/E (ttm): 15.85
EPS (ttm): 1.43
Div & Yield: N/A (N/A%)
Endo Pharmaceuticals Holdings Inc. (ENDP)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add ENDP to Portfolio   Download Data

HEADLINES
• Which Drug Companies Could Be Private-Equity Targets?
at The Wall Street Journal Online (Mon 10:00am)
• ENDO PHARMACEUTICALS HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 13)
• Endo paying $23M to settle patent dispute with LecTec
at bizjournals.com (Thu, Nov 12)
• UPDATE - Endo and LecTec settle patent dispute
at Reuters (Wed, Nov 11)
• Endo paying $23 million to settle patent dispute
AP (Wed, Nov 11)
• Endo Pharmaceuticals and LecTec Settle Patent Dispute
PRNewswire (Wed, Nov 11)
• Endo makes first milestone payment to Bioniche for bladder cancer drug
at bizjournals.com (Fri, Nov 6)
• UPDATE - Bioniche gets $6 mln milestone payment from Endo Pharma
at Reuters (Fri, Nov 6)
• Indian Pharmaceutical Stock Picks From Citi Investment Research: The Sub Continent Goes Global WIth Drug Manufacturing Partnerships
Wall Street Transcript (Thu, Nov 5)
• ENDO PHARMACEUTICALS HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Wed, Nov 4)
• ENDO PHARMACEUTICALS HOLDINGS INC Financials
EDGAR Online Financials (Wed, Nov 4)
More Headlines for ENDP...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : 2.08
Avg Rec (current)*: 2.1
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Endo Pharmaceuticals Holdings, Inc. engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices